On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.

David Pope, PharmD, Chief Pharmacy Officer at XiPhin, shared his thoughts on value-based care and how it is used within a pharmacy setting.

As health care systems and the current syndemic continue to evolve, pharmacies are poised to play a crucial role in improving public health.

Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

Jon Minkin, enterprise account executive at NimbleRx, shared how his company can help independent pharmacies unlock revenue opportunities.

Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.

In case you missed it, this week we had stories about medication-related disaster preparedness, COVID-19 and cardiovascular risks, legal battles over inflated insulin prices, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of October 7.

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

The approval is supported by results from phase 3 multi-regional clinical trials conducted in patients with plaque psoriasis.

Recent research on vitamin D supplementation and respiratory tract infections can help guide pharmacists in counseling patients.

In an interview with Drug Topics, TaQuina Warren, PharmD, discussed what it means to serve her community and how she has garnered a reputation within her profession.

Individuals living in rural areas can benefit from pharmacy-based pre-exposure prophylaxis programs.

Additional research is needed to determine if the therapy can help with cognitive symptoms of post–COVID-19 condition.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

The partnership will provide tools to address both patient and pharmacist well-being amid the current mental health crisis.

Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.

Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.

The therapy’s Prescription Drug User Fee Act date has been set for July 26, 2025.